EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Population‐specific validation and comparison of the performance of 77‐ and 313‐variant polygenic risk scores for breast cancer risk prediction

Milena Hovhannisyan, Petra Zemankova, Petr Nehasil, Katerina Matejkova, Marianna Borecka, Marta Cerna, Tatana Dolezalova, Lenka Dvorakova, Lenka Foretova, Klara Horackova, Sandra Jelinkova, Pavel Just und 15 weitere

Cancer · 2024

DOI: 10.1002/cncr.35337 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer, 2024. Verfasst von Milena Hovhannisyan und 26 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague…. Hauptthemen laut MEDLINE: Breast Neoplasms, Genetic Predisposition to Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Education, Youth and Sports of the Czech Republic, Ministry of Health of the Czech Republic, Grant Agency, Charles University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The polygenic risk score (PRS) allows the quantification of the polygenic effect of many low‐penetrance alleles on the risk of breast cancer (BC). This study aimed to evaluate the performance of two sets comprising 77 or 313 low‐penetrance loci (PRS77 and PRS313) in patients with BC in the Czech population.

Methods

In a retrospective case‐control study, variants were genotyped from both the PRS77 and PRS313 sets in 1329 patients with BC and 1324 noncancer controls, all women without germline pathogenic variants in BC predisposition genes. Odds ratios (ORs) were calculated according to the categorical PRS in individual deciles. Weighted Cox regression analysis was used to estimate the hazard ratio (HR) per standard deviation (SD) increase in PRS.

Results

The distributions of standardized PRSs in patients and controls were significantly different ( p < 2.2 × 10 −16 ) with both sets. PRS313 outperformed PRS77 in categorical and continuous PRS analyses. For patients in the highest 2.5% of PRS313, the risk reached an OR of 3.05 (95% CI, 1.66–5.89; p = 1.76 × 10 −4 ). The continuous risk was estimated as an HR per SD of 1.64 (95% CI, 1.49–1.81; p < 2.0 × 10 −16 ), which resulted in an absolute risk of 21.03% at age 80 years for individuals in the 95th percentile of PRS313. Discordant categorization into PRS deciles was observed in 248 individuals (9.3%).

Conclusions

Both PRS77 and PRS313 are able to stratify individuals according to their BC risk in the Czech population. PRS313 shows better discriminatory ability. The results support the potential clinical utility of using PRS313 in individualized BC risk prediction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsGenetic Predisposition to DiseaseHumansFemaleCase-Control StudiesMiddle AgedRetrospective StudiesAgedMultifactorial InheritanceAdultRisk AssessmentCzech RepublicRisk FactorsGenetic Risk Score

Stichwörter der Autor:innen

PRS313PRS77breast cancergermline genetic testingpolygenic risk score

Autor:innen und Institutionen

  • Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • Department of Genetics and Microbiology, Faculty of Science, Charles University in Prague, Prague, Czech Republic.
  • Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Centre for Medical Genetics and Reproductive Medicine, GENNET, Prague, Czech Republic.

ORCID-Profile: Corinna Ernst, Zdenek Kleibl, Marketa Janatova

Förderung

  • Ministry of Education, Youth and Sports of the Czech Republic
  • Ministry of Health of the Czech Republic
  • Grant Agency, Charles University

Zitieren

APA

Hovhannisyan, M., Zemankova, P., Nehasil, P., Matejkova, K., Borecka, M., Cerna, M., Dolezalova, T., Dvorakova, L., Foretova, L., Horackova, K., Jelinkova, S., Just, P., Kalousova, M., Kral, J., Machackova, E., Nemcova, B., Safarikova, M., Springer, D., Stastna, B., …, & Janatova, M. (2024). Population‐specific validation and comparison of the performance of 77‐ and 313‐variant polygenic risk scores for breast cancer risk prediction. Cancer. https://doi.org/10.1002/cncr.35337

Vancouver

Hovhannisyan M, Zemankova P, Nehasil P, Matejkova K, Borecka M, Cerna M, et al. Population‐specific validation and comparison of the performance of 77‐ and 313‐variant polygenic risk scores for breast cancer risk prediction. Cancer. 2024. doi:10.1002/cncr.35337

BibTeX
@article{Hovhannisyan2024,
  author = {Hovhannisyan, Milena and Zemankova, Petra and Nehasil, Petr and Matejkova, Katerina and Borecka, Marianna and Cerna, Marta and Dolezalova, Tatana and Dvorakova, Lenka and Foretova, Lenka and Horackova, Klara and Jelinkova, Sandra and Just, Pavel and Kalousova, Marta and Kral, Jan and Machackova, Eva and Nemcova, Barbora and Safarikova, Marketa and Springer, Drahomira and Stastna, Barbora and Tavandzis, Spiros and Vocka, Michal and Zima, Tomas and Soukupova, Jana and Kleiblova, Petra and Ernst, Corinna and Kleibl, Zdenek and Janatova, Marketa},
  title = {Population‐specific validation and comparison of the performance of 77‐ and 313‐variant polygenic risk scores for breast cancer risk prediction},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35337}
}
Kostenlos starten →